| Literature DB >> 19019918 |
Eisei Noiri1, Kent Doi, Kousuke Negishi, Tamami Tanaka, Yoshifumi Hamasaki, Toshiro Fujita, Didier Portilla, Takeshi Sugaya.
Abstract
In the development of novel therapeutic strategies for kidney disease, new renal biomarkers for early detection and accurate evaluation of renal injury are urgently required for both acute kidney injury (AKI) and chronic kidney disease (CKD). Fatty acid-binding protein 1 (FABP1) is expressed in renal proximal tubule cells and shed into urine in response to hypoxia caused by decreased peritubular capillary blood flow. To clarify the role of urinary FABP1 in kidney disease, we established human FABP1 transgenic mice and evaluated the responses of FABP1 to several AKI and CKD models. Moreover, there are accumulating clinical data that urinary FABP1 can detect human AKI earlier than serum creatinine and can distinguish the risk population for AKI. Investigation with "humanized" FABP1 transgenic mice and measurement of clinical samples allowed us to develop urinary FABP1 as a new renal biomarker. Further clinical studies are necessary to confirm the potential of urinary FABP1 for clinical application.Entities:
Mesh：
Substances：
Year: 2008 PMID： 19019918 PMCID： PMC2670638 DOI： 10.1152/ajprenal.90513.2008
Source DB: PubMed Journal: Am J Physiol Renal Physiol ISSN： 1522-1466